User profiles for Palaniappan Kulanthaivel

Palaniappan Kulanthaivel

Vice President, Pyramid Biosciences
Verified email at pyramidbio.com
Cited by 5430

Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors

…, AD Fulford, TS Nguyen, R Martinez, P Kulanthaivel… - Cancer discovery, 2016 - AACR
We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor
activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 …

Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an …

TJ Raub, GN Wishart, P Kulanthaivel, BA Staton… - Drug Metabolism and …, 2015 - ASPET
Effective treatments for primary brain tumors and brain metastases represent a major unmet
medical need. Targeting the CDK4/CDK6-cyclin D1-Rb-p16/ink4a pathway using a potent …

Balanol: a novel and potent inhibitor of protein kinase C from the fungus Verticillium balanoides

P Kulanthaivel, YF Hallock, C Boros… - Journal of the …, 1993 - ACS Publications
Protein kinase C (PKC), a family of serine/threonine-specific kinases, plays a key role in cell
growth, metabolism, and differentiation. 1 Because the activated enzyme has been impli-…

Selective metabolism of vincristine in vitro by CYP3A5

JB Dennison, P Kulanthaivel, RJ Barbuch… - Drug metabolism and …, 2006 - ASPET
Clinical outcomes of vincristine therapy, both neurotoxicity and efficacy, are unpredictable,
and the reported pharmacokinetics of vincristine have considerable interindividual variability. …

A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds

…, MMY Chen, P Kulanthaivel… - … A European Journal, 2009 - Wiley Online Library
Herein we demonstrate that a small panel of variants of cytochrome P450 BM3 from Bacillus
megaterium covers the breadth of reactivity of human P450s by producing 12 of 13 …

Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells

…, WJ Ehlhardt, DA Jackson, P Kulanthaivel… - Chemical research in …, 2003 - ACS Publications
Capsaicin is a common dietary constituent and a popular homeopathic treatment for chronic
pain. Exposure to capsaicin has been shown to cause various dose-dependent acute …

A first-in-human phase I study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 dimesylate), in patients with advanced cancer

…, LF Stancato, R Bell, P Shi, P Kulanthaivel… - Clinical Cancer …, 2016 - AACR
Purpose: p38 MAPK regulates the production of cytokines in the tumor microenvironment
and enables cancer cells to survive despite oncogenic stress, radiotherapy, chemotherapy, …

Discovery of cercosporamide, a known antifungal natural product, as a selective Pkc1 kinase inhibitor through high-throughput screening

…, G Zhu, RM Campbell, TS Park, P Kulanthaivel… - Eukaryotic …, 2004 - Am Soc Microbiol
The Pkc1-mediated cell wall integrity-signaling pathway is highly conserved in fungi and is
essential for fungal growth. We thus explored the potential of targeting the Pkc1 protein …

[HTML][HTML] Novel lipoglycopeptides as inhibitors of bacterial signal peptidase I

P Kulanthaivel, AJ Kreuzman, MA Strege… - Journal of Biological …, 2004 - ASBMB
Signal peptidase (SPase) I is responsible for the cleavage of signal peptides of many secreted
proteins in bacteria. Because of its unique physiological and biochemical properties, it …

[HTML][HTML] A population pharmacokinetic and pharmacodynamic analysis of abemaciclib in a phase I clinical trial in cancer patients

SC Tate, AK Sykes, P Kulanthaivel, EM Chan… - Clinical …, 2018 - Springer
Background and Objectives Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and
6, has demonstrated clinical activity in a number of different cancer types. The objectives of …